About Us

Our company was founded in 2006 to offer a novel treatment for IgA nephropathy. Its founders discovered and characterized IgA proteases during more than forty years of research conducted at Tufts University School of Medicine. These enzymes offer a new appraoch to treatment of IgA nephropathy because they directly target IgA deposits that are believed to have a central role in the development of the disease.